LUNA Price Up 20% in 24 Hours as Terra Network Upgrade Proceeds

On DEC 5 2025, LUNA rose by 20% within 24 hours to reach $0.0868, LUNA rose by 22.99% within 7 days, rose by 22.99% within 1 month, and dropped by 78.59% within 1 year.

Terra Network to Undergo Scheduled Upgrade

The Terra network is set to undergo a major upgrade on December 8, 2025, at block height 18,660,000. As part of the upgrade process, Binance announced that it will temporarily halt LUNA (Terra) deposits and withdrawals beginning at 20:05 UTC+8 on the same day to ensure a secure and seamless transition during the protocol upgrade. The network upgrade is expected to be completed around 21:05 UTC+8.

This maintenance window is a standard procedure during major blockchain upgrades and is intended to prevent potential disruptions in transaction processing. Users are advised to monitor Binance’s official communication channels for real-time updates and confirmation of service restoration.

Biotech Company Reports Positive LUNA Trial Outcomes

Separately, Adverum Biotechnologies, Inc. released two-year follow-up results from its LUNA Phase 2 trial for Ixo-vec in wet AMD patients on December 4, 2025. The trial data showed a ~90% reduction in anti-VEGF injections over the two-year period, with sustained anatomic control and visual acuity in both dose groups. The 6E10 dose group also reported no new inflammation after week 30. Ixo-vec continues to demonstrate a favorable safety profile.

The findings support the ongoing development of the therapy, with the Phase 3 ARTEMIS trial expected to reach full enrollment by December 5, 2025. The biotech firm has emphasized the potential of Ixo-vec as a transformative treatment for wet AMD, with a focus on reducing the frequency of injections compared to current standard-of-care.

Conclusion

With LUNA experiencing significant short-term price gains, the upcoming Terra network upgrade and the biotech firm’s trial results are key events shaping market sentiment. The upgrade will be critical for the blockchain’s long-term stability, while Adverum’s clinical data adds further credibility to its pipeline, potentially influencing broader perceptions of the LUNA brand beyond the crypto sector.